CoChat

Ketoconazole and Posaconazole Selectively Target HK2-expressing Glioblastoma Cells

Open access
Agnihotri, Sameer, Mansouri, Sheila, Burrell, Kelly, Li, Mira, Mamatjan, Yasin, Liu, Jeff, Nejad, Romina, Kumar, Sushil, Jalali, Shahrzad, Singh, Sanjay K., Vartanian, Alenoush, Chen, Eric Xueyu, Karimi, Shirin, Singh, Olivia, Bunda, Severa, Mansouri, Alireza, Aldape, Kenneth D., Zadeh, Gelareh · 2019 · Clinical Cancer Research
Cited by 73

The DOI matches its Crossref record; 5 of the 5 references it cites were found in a registry or an index.

Abstract

Purpose: Hexokinase II (HK2) protein expression is elevated in glioblastoma (GBM), and we have shown that HK2 could serve as an effective therapeutic target for GBM. Here, we interrogated compounds that target HK2 effectively and restrict tumor growth in cell lines, patient-derived glioma stem cells (GSCs), and mouse models of GBM. Experimental Design: We performed a screen using a set of 15 drugs that were predicted to inhibit the HK2-associated gene signature. We next determined the EC50 of the compounds by treating glioma cell lines and GSCs. Selected compounds showing significant impact in vitro were used to treat mice and examine their effect on survival and tumor characteristics. The effect of compounds on the metabolic activity in glioma cells was also assessed in vitro. Results: This screen identified the azole class of antifungals as inhibitors of tumor metabolism. Among the compounds tested, ketoconazole and posaconazole displayed the greatest inhibitory effect on GBM both in vitro and in vivo. Treatment of mice bearing GBM with ketoconazole and posaconazole increased their survival, reduced tumor cell proliferation, and decreased tumor metabolism. In addition, treatment with azoles resulted in increased proportion of apoptotic cells. Conclusions: Overall, we provide evidence that azoles exert their effect by targeting genes and pathways regulated by HK2. These findings shed light on the action of azoles in GBM. Combined with existing literature and preclinical results, these data support the value of repurposing azoles in GBM clinical trials.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1158/1078-0432.ccr-18-1854

Cites

5 of 5 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 5 references

Cited by

See all 73

Metadata

Authors
Agnihotri, S., Mansouri, S., Burrell, K., Li, M., Mamatjan, Y., Liu, J., Nejad, R., Kumar, S., Jalali, S., Singh, S. K., Vartanian, A., Chen, E. X., Karimi, S., Singh, O., Bunda, S., Mansouri, A., Aldape, K. D., & Zadeh, G.
Venue
Clinical Cancer Research
Published
2019-01-15
Volume
25
Issue
2
Pages
844-855
ISSN
  • 1078-0432 (ISSN-L)
  • 1557-3265
OpenAlex
W2896952615
Cited by
73
References
5
FWCI
1.49
Type
journal article
Language
en
Open access
green

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Ketoconazole and Posaconazole Selectively Target HK2-expressing Glioblastoma Cells. https://app.cochat.ai/papers/10.1158/1078-0432.ccr-18-1854
The paper
Agnihotri, S., Mansouri, S., Burrell, K., Li, M., Mamatjan, Y., Liu, J., Nejad, R., Kumar, S., Jalali, S., Singh, S. K., Vartanian, A., Chen, E. X., Karimi, S., Singh, O., Bunda, S., Mansouri, A., Aldape, K. D., & Zadeh, G. (2019). Ketoconazole and Posaconazole Selectively Target HK2-expressing Glioblastoma Cells. Clinical Cancer Research. https://doi.org/10.1158/1078-0432.ccr-18-1854

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.